Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 10/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.58 |
| ▸ | ACP1 | P24666 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | TEK | Q02763 | 1/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23256576 | 0.92 | CSNK1D (0.63) | CSNK1DDYRK1AACP1HSD17B10CYP2D6 | |
| SCHEMBL23256577 | 0.92 | CSNK1D (0.63) | CSNK1DDYRK1AACP1HSD17B10CYP2D6 | |
| SCHEMBL23256575 | 0.92 | CSNK1D (0.63) | CSNK1DDYRK1AACP1HSD17B10CYP2D6 | |
| SCHEMBL21568184 | 0.91 | CSNK1D (0.62) | CSNK1DDYRK1AACP1HSD17B10CYP2D6 | |
| SCHEMBL21568183 | 0.91 | CSNK1D (0.62) | CSNK1DDYRK1AACP1HSD17B10 | |
| SCHEMBL23256629 | 0.91 | CSNK1D (0.62) | CSNK1DDYRK1AACP1HSD17B10 | |
| SCHEMBL21568248 | 0.87 | CSNK1D (0.70) | CSNK1DDYRK1AACP1HSD17B10CYP2D6 | |
| SCHEMBL21568266 | 0.86 | NPC1 (0.56) | DYRK1AHSD17B10DYRK1B | |
| SCHEMBL21568188 | 0.85 | DYRK1A (0.61) | CSNK1DDYRK1AACP1HSD17B10KDR | |
| SCHEMBL23256548 | 0.84 | CSNK1D (0.61) | CSNK1DDYRK1AACP1HSD17B10CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2021-04-22 | — | — | US | disclosed |
| WO-2019217509-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | VHL, TP53, NUDT1 | CSNK1D 3599/4885DYRK1A 4664/4885ACP1 2554/4885 |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | VHL, TP53, NUDT1 | CSNK1D 3509/4885DYRK1A 4618/4885ACP1 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.